Mars Finance News, July 18: According to disclosures by the Hong Kong Stock Exchange, from July 13 to 18, a total of six companies submitted listing prospectuses to the Hong Kong Stock Exchange, including Boke Electronics, Jianbang Metals, Weizhao Semiconductor, Uf Y Tech, Yinuowei, and Baojiyuan, among others. Among them, Uf Y Tech is already listed on the A-share market, with a latest market value of 30.138 billion yuan. Jianbang Metals is a supplier of silver powder, with integrated research, development, production, and sales capabilities. The prospectus shows that Jianbang Metals’ revenue in 2023, 2024, and 2025 was 2.782 billion yuan, 3.95 billion yuan, and 5.067 billion yuan, respectively; gross profit was 107 million yuan, 131 million yuan, and 236 million yuan, respectively; and profit during the period was 59.89 million yuan, 79.08 million yuan, and 169 million yuan, respectively. Its revenue for the first five months of 2026 was 4.05 billion yuan, gross profit was 80.76 million yuan, and profit during the period was 55.71 million yuan. Uf Y Tech is making a third attempt to list in Hong Kong. On June 27, 2025, the company first submitted its listing application to the Hong Kong Stock Exchange, and it then lapsed in December. On December 29 of the same year, Uf Y Tech quickly filed its second application; according to the Hong Kong Stock Exchange’s relevant rules, if no hearing is passed within 6 months after the filing, the application automatically becomes invalid. On the evening of July 14, Uf Y Tech disclosed its 2026 first-half performance forecast. The company expects to achieve revenue of 3.65 billion yuan to 3.7 billion yuan in the first half, up 1.9% to 3.3% year on year. Net loss attributable to owners of the parent company is expected to be 800 million yuan to 930 million yuan, compared with a loss of 945 million yuan in the same period last year. Yinuowei was founded in 2015 and is headquartered in Suzhou, Jiangsu. It focuses on the R&D and commercialization of oncolytic immunotherapy and engineered exosome therapy. It has two clinical-stage oncolytic immunotherapy candidate drugs, two pre-clinical-stage engineered exosome therapy candidate drugs, and three engineered exosome products that can be commercialized directly, including one that has completed registration via the INCI route. As of the time of submitting the application, all pipeline products have not completed Phase III clinical trials, have not yet obtained approval from regulators in China and the United States, and therefore cannot guarantee that subsequent Phase II or Phase III clinical trials will achieve the primary efficacy endpoints. Financial data shows that from 2023 to 2025, the company’s revenue was 6.77 million yuan, 3.2 million yuan, and 1.31 million yuan, respectively; gross losses were 16.74 million yuan, 9.237 million yuan, and 1.52 million yuan, respectively; and losses during the period were 482 million yuan, 524 million yuan, and 519 million yuan, respectively, with a cumulative loss of 1.525 billion yuan over the three years. (KeGuBao report)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
PreIPOsSeason2OpenAISubscription
1.33M Popularity
#
GateDEXIntegratesWithRobinhoodChain
763.98K Popularity
#
TSMCQ2NetProfitSurges77%
264.61K Popularity
#
SummerCreationCamp
1.04M Popularity
#
USDTDepositEarningsDoublePlay
29.14M Popularity

Pinned

Sitemap

This week, 6 companies including Jiabang Metal and UFIDA Network filed applications with the Hong Kong Stock Exchange.

Trending Topics

PreIPOsSeason2OpenAISubscription

GateDEXIntegratesWithRobinhoodChain

TSMCQ2NetProfitSurges77%

SummerCreationCamp

USDTDepositEarningsDoublePlay

Pinned